Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT 131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.
1. A method of treating nonalcoholic steatohepatitis (NASH) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein the subject is a human, and
wherein the therapeutically effective amount is from 0.1 mg to 10 mg.
2. The method of claim 1 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is from 0.5 mg to 5 mg.
3. The method of claim 2 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is from 1 mg to 3 mg.
4. The method of claim 3 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is 1 mg.
5. The method of claim 3 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is 1.5 mg.
6. The method of claim 3 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is 2 mg.
7. The method of claim 3 , wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is 3 mg.
8. The method of claim 1 , wherein the compound of the formula (I) is administered as a pharmaceutically acceptable salt.
9. The method of claim 8 , wherein the pharmaceutically acceptable salt of the compound of formula (I) is the besylate salt.
10. The method of claim 9 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to from 0.5 mg to 5 mg of the free base.
11. The method of claim 10 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to from 1 mg to 3 mg of the free base.
12. The method of claim 11 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to 1 mg of the free base.
13. The method of claim 11 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to 1.5 mg of the free base.
14. The method of claim 11 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to 2 mg of the free base.
15. The method of claim 11 , wherein the amount of the besylate salt of the compound of formula (I), is equivalent to 3 mg of the free base.